Rocket Pharmaceuticals, Inc.
NASDAQ:RCKTBiotechnology
+$0.06 today
- Market cap
- $235.60M
- Beta
- 0.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$1.87
Volume 2.49M
Average 3.15M
RCKT Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Rocket Pharmaceuticals, Inc.NASDAQ: RCKT
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) grows, but more slowly than its trailing trend
Q1 FY2026 weighted avg shares (diluted) of 112.13M shares rose 1.9% year over year, behind the +12.7% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.9% from the prior quarter. Over 3 fiscal years it compounded at +17.7% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +1.9% toward the trailing-twelve-month pace of +12.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 111.12M USD
- Year-over-year change
- +17.2%
- 4-year CAGR
- +15.1%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 111.12M | +17.2% |
| FY2024 | 2024-12-31 | 94.81M | +12.9% |
| FY2023 | 2023-12-31 | 84.01M | +23.3% |
| FY2022 | 2022-12-31 | 68.15M | +7.8% |
| FY2021 | 2021-12-31 | 63.24M | — |
Weighted Avg Shares (Diluted) vs competitors
How RCKT compares with its peers on the latest reported figures
- RCKT's LTM Mar 2026 weighted avg shares (diluted) of 111.46M shares is the 4th highest of the 10 companies compared; the peer median is 88.66M shares.
- Its year-over-year change of +12.7% is the 5th highest of 9, against a peer median of +8.5%.
- Over three fiscal years its annual growth of +17.7% compares with a peer median of +26.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 266.14M | +0.0% | +41.0% | |
| LTM Mar 2026 | 201.73M | +31.6% | +12.4% | |
| LTM Mar 2026 | 161.69M | +14.3% | +41.6% | |
| LTM Mar 2026 | 111.46M | +12.7% | +17.7% | |
| LTM Mar 2026 | 98.28M | +94.3% | +117.4% | |
| LTM Mar 2026 | 88.66M | -7.8% | +3.7% | |
| LTM Mar 2026 | 64.33M | +2.7% | +2.5% | |
| LTM Mar 2026 | 62.93M | +26.5% | +26.3% | |
| LTM Mar 2026 | 58.14M | +2.6% | +1.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | 19.77M | — | +92.6% |
| Peer median (excluding RCKT) | 88.66M | +8.5% | +26.3% | |
Competitors are the stored peer set for RCKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 11.03M |
| Gross Profit | 0 | 0 | 0 | 0 | (11.03M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 125.48M | 165.57M | 186.34M | 171.24M | 142.02M |
| Selling, General & Admin | 41.77M | 58.77M | 73.32M | 101.96M | 86.5M |
| Operating Expenses | 167.25M | 224.34M | 259.66M | 273.21M | 217.49M |
| Depreciation & Amortization | 5.37M | 6.27M | 7.1M | 9.38M | 11.03M |
| EBITDA | (157.81M) | (213.69M) | (236.62M) | (247.49M) | (210.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (167.25M) | (224.34M) | (259.66M) | (273.21M) | (228.52M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 3.07M | 3.89M | 15.94M | 18.22M | 10.62M |
| Interest Expense | 5.89M | 1.91M | 1.88M | 1.89M | 1.89M |
| Other Income / Expenses | (1.82M) | 2.48M | 14.06M | 14.46M | 5.39M |
| Income Before Tax | (169.07M) | (221.86M) | (245.6M) | (258.75M) | (223.12M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (169.07M) | (221.86M) | (245.6M) | (258.75M) | (223.12M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.68) | (3.26) | (2.92) | (2.73) | (2.01) |
| EPS (Diluted) | (2.68) | (3.26) | (2.92) | (2.73) | (2.01) |
| Weighted Avg Shares | 63.24M | 68.15M | 84.01M | 94.81M | 111.12M |
| Weighted Avg Shares (Diluted) | 63.24M | 68.15M | 84.01M | 94.81M | 111.12M |
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
Intrinsic Alpha fair value
Locked
Current Price
$2.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.